RIPK3 and colorectal carcinoma: In vivo experiments further confirmed that RBG (5 and 10 mg/kg) dose-dependently inhibited the weight and volume of tumors in CRC model mice, and western blot results showed that RBG was able to upregulate the levels of PYGL, GLUD1, GLUL, RIPK3, and MLKL.